Mistral Pharma Inc. (TSX VENTURE: MIP) announced today that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for its MIST-B03 product. MIST-B03 is a reformulation of different drugs which are already marketed for the treatment of various inflammatory diseases. This patent application was filed by the Montreal office of Bereskin & Parr, a leading patent agent firm.
